On the 29th August an ACE moderator answered a question about the oral anticoagulant Pradaxa.
It was stated that the drug has a licence for the prevention of deep vein thrombosis and pulmonary embolism.
This is incorrect.
Pradaxa is licenced for the prevention of stroke in people with non-valvular atrial fibrillation and the prevention of VTE (deep vein thrombosis and pulmonary embolism) in people undergoing elective hip and knee replacement surgery.
We would like to apologise for any confusion caused by this.
Written by
warfarin1
To view profiles and participate in discussions please or .
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.